6 O
ADVERSE O
REACTIONS O
Serious O
and O
important O
adverse O
reactions O
described O
elsewhere O
in O
labeling O
include O
: O
* O
Gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Severe O
or O
persistent O
diarrhea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
1 O
% O
) O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
are O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hyperhidrosis B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
chills B-OSE_Labeled_AE
( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
5 O
% O
) O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
are O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
diarrhea B-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Salix O
Pharmaceuticals O
Inc O
. O
at O
1-800-508-0024 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Opioid-Induced O
Constipation O
in O
Adult O
Patients O
with O
Chronic O
Non-Cancer O
Pain O
The O
safety O
of O
RELISTOR O
was O
evaluated O
in O
a O
double-blind O
, O
placebo-controlled O
trial O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
receiving O
opioid O
analgesia O
. O

This O
study O
( O
Study O
1 O
) O
included O
a O
4-week O
, O
double-blind O
, O
placebo-controlled O
period O
in O
which O
adult O
patients O
were O
randomized O
to O
receive O
RELISTOR O
12 O
mg O
once O
daily O
( O
150 O
patients O
) O
or O
placebo O
( O
162 O
patients O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

After O
4 O
weeks O
of O
double-blind O
treatment O
, O
patients O
began O
an O
8-week O
open-label O
treatment O
period O
during O
which O
RELISTOR O
12 O
mg O
was O
administered O
less O
frequently O
than O
the O
recommended O
dosage O
regimen O
of O
12 O
mg O
once O
daily O
. O

Adverse O
reactions O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
receiving O
RELISTOR O
are O
shown O
in O
Table O
2 O
. O

The O
adverse O
reactions O
in O
the O
table O
below O
may O
reflect O
symptoms O
of O
opioid B-NonOSE_AE
withdrawal I-NonOSE_AE
. O

Table O
2 O
: O
Adverse O
Reactions* O
in O
4-Week O
Double-Blind O
, O
Placebo-Controlled O
Period O
of O
Clinical O
Study O
of O
RELISTOR O
in O
Adult O
Patients O
with O
Opioid-InducedConstipation O
and O
Chronic O
Non-Cancer O
Pain O
Adverse O
Reaction O
RELISTOR O
12 O
mg O
once O
dailyn O
= O
150 O
Placebo O
n O
= O
162 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
21 O
% O
6 O
% O
Nausea B-OSE_Labeled_AE
9 O
% O
6 O
% O
Diarrhea B-OSE_Labeled_AE
6 O
% O
4 O
% O
Hyperhidrosis B-OSE_Labeled_AE
6 O
% O
1 O
% O
Hot B-OSE_Labeled_AE
Flush I-OSE_Labeled_AE
3 O
% O
2 O
% O
Tremor B-OSE_Labeled_AE
1 O
% O
< O
1 O
% O
Chills B-OSE_Labeled_AE
1 O
% O
0 O
% O
*Adverse O
reactions O
occuring O
in O
> O
= O
1 O
% O
of O
patients O
receiving O
RELISTOR O
12 O
mg O
once O
daily O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

. O

During O
the O
4-week O
double-blind O
period O
, O
in O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
that O
received O
RELISTOR O
12 O
mg O
every O
other O
day O
, O
there O
was O
a O
higher O
incidence O
of O
adverse O
reactions O
, O
including O
nausea B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
12 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
tremor B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
feeling B-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
change I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
piloerection B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
chills B-OSE_Labeled_AE
( O
2 O
% O
) O
as O
compared O
to O
daily O
Relistor O
dosing O
. O

Use O
of O
RELISTOR O
12 O
mg O
every O
other O
day O
is O
not O
recommended O
in O
patients O
with O
OIC B-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

The O
rates O
of O
discontinuation O
due O
to O
adverse O
reactions O
during O
the O
double-blind O
period O
( O
Study O
1 O
) O
were O
higher O
in O
the O
RELISTOR O
once O
daily O
( O
7 O
% O
) O
than O
the O
placebo O
group O
( O
3 O
% O
) O
. O

Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
was O
the O
most O
common O
adverse O
reaction O
resulting O
in O
discontinuation O
from O
the O
double-blind O
period O
in O
the O
RELISTOR O
once O
daily O
group O
( O
2 O
% O
) O
. O

The O
safety O
of O
RELISTOR O
was O
also O
evaluated O
in O
a O
48-week O
, O
open-label O
, O
uncontrolled O
trial O
in O
1034 O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
chronic B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
pain I-Not_AE_Candidate
( O
Study O
2 O
) O
. O

Patients O
were O
allowed O
to O
administer O
RELISTOR O
12 O
mg O
less O
frequently O
than O
the O
recommended O
dosage O
regimen O
of O
12 O
mg O
once O
daily O
, O
and O
took O
a O
median O
of O
6 O
doses O
per O
week O
. O

A O
total O
of O
624 O
patients O
( O
60 O
% O
) O
completed O
at O
least O
24 O
weeks O
of O
treatment O
and O
477 O
( O
46 O
% O
) O
completed O
the O
48-week O
study O
. O

The O
adverse O
reactions O
seen O
in O
this O
study O
were O
similar O
to O
those O
observed O
during O
the O
4-week O
double-blind O
period O
of O
Study O
1 O
. O

Additionally O
, O
in O
Study O
2 O
, O
investigators O
reported O
4 O
myocardial B-NonOSE_AE
infarctions I-NonOSE_AE
( O
1 O
fatal B-NonOSE_AE
) O
, O
1 O
stroke B-NonOSE_AE
( O
fatal B-NonOSE_AE
) O
, O
1 O
fatal B-NonOSE_AE
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
and O
1 O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

It O
is O
not O
possible O
to O
establish O
a O
relationship O
between O
these O
events O
and O
RELISTOR O
. O

Opioid-Induced O
Constipation O
in O
Adult O
Patients O
with O
Advanced O
Illness O
The O
safety O
of O
RELISTOR O
was O
evaluated O
in O
two O
, O
double-blind O
, O
placebo-controlled O
trials O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
receiving O
palliative O
care O
: O
Study O
3 O
included O
a O
single-dose O
, O
double-blind O
, O
placebo-controlled O
period O
, O
whereas O
Study O
4 O
included O
a O
14-day O
multiple O
dose O
, O
double-blind O
, O
placebo-controlled O
period O
[ O
see O
Clinical O
Studies O
( O
14 O
.2 O
) O
] O
. O

The O
most O
common O
( O
> O
= O
5 O
% O
) O
adverse O
reactions O
in O
adult O
patients O
with O
opioid B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
constipation I-Not_AE_Candidate
and O
advanced O
illness O
receiving O
RELISTOR O
are O
shown O
in O
Table O
3 O
below O
. O

Table O
3 O
: O
Adverse O
Reactions O
from O
all O
Doses O
in O
Double-Blind O
, O
Placebo-Controlled O
Clinical O
Studies O
of O
RELISTOR O
in O
Adult O
Patients O
with O
Opioid-Induced O
Constipation O
and O
Advanced O
Illness* O
Adverse O
Reaction O
RELISTORn O
= O
165 O
Placebon O
= O
123 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
29 O
% O
10 O
% O
Flatulence B-OSE_Labeled_AE
13 O
% O
6 O
% O
Nausea B-OSE_Labeled_AE
12 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
7 O
% O
2 O
% O
Diarrhea B-OSE_Labeled_AE
6 O
% O
2 O
% O
* O
Adverse O
reactions O
occuring O
in O
> O
= O
5 O
% O
of O
patients O
receiving O
all O
doses O
of O
RELISTOR O
( O
0.075 O
, O
0.15 O
, O
and O
0.30 O
mg/kg/dose O
) O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

The O
rates O
of O
discontinuation O
due O
to O
adverse O
events O
during O
the O
double-blind O
placebo O
controlled O
clinical O
trials O
( O
Study O
3 O
and O
Study O
4 O
) O
were O
comparable O
between O
RELISTOR O
( O
1 O
% O
) O
and O
placebo O
( O
2 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
RELISTOR O
. O

Because O
they O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Gastrointestinal B-NonOSE_AE
Perforation O
, O
cramping O
, O
vomiting B-OSE_Labeled_AE
Gen B-NonOSE_AE
eral I-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administrative I-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Diaphoresis B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
. O

Cases O
of O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
have O
been O
reported O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

